Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Irritable Bowel Syndrome HELP
Based on 4,113 articles since 2006
||||

These are the 4113 published articles about Irritable Bowel Syndrome that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Evidence-based clinical practice guidelines for irritable bowel syndrome. 2015

Fukudo, Shin / Kaneko, Hiroshi / Akiho, Hirotada / Inamori, Masahiko / Endo, Yuka / Okumura, Toshikatsu / Kanazawa, Motoyori / Kamiya, Takeshi / Sato, Ken / Chiba, Toshimi / Furuta, Kenji / Yamato, Shigeru / Arakawa, Tetsuo / Fujiyama, Yoshihide / Azuma, Takeshi / Fujimoto, Kazuma / Mine, Tetsuya / Miura, Soichiro / Kinoshita, Yoshikazu / Sugano, Kentaro / Shimosegawa, Tooru. ·Guidelines Committee for creating and evaluating the "Evidence-based clinical practice guidelines for irritable bowel syndrome", the Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13 Ginza, Chuo, Tokyo, 104-0061, Japan, sfukudo@med.tohoku.ac.jp. · ·J Gastroenterol · Pubmed #25500976.

ABSTRACT: New strategies for the care of irritable bowel syndrome (IBS) are developing and several novel treatments have been globally produced. New methods of care should be customized geographically because each country has a specific medical system, life style, eating habit, gut microbiota, genes and so on. Several clinical guidelines for IBS have been proposed and the Japanese Society of Gastroenterology (JSGE) subsequently developed evidence-based clinical practice guidelines for IBS. Sixty-two clinical questions (CQs) comprising 1 definition, 6 epidemiology, 6 pathophysiology, 10 diagnosis, 30 treatment, 4 prognosis, and 5 complications were proposed and statements were made to answer to CQs. A diagnosis algorithm and a three-step treatment was provided for patients with chronic abdominal pain or abdominal discomfort and/or abnormal bowel movement. If more than one alarm symptom/sign, risk factor and/or routine examination is positive, colonoscopy is indicated. If all of them, or the subsequent colonoscopy, are/is negative, Rome III or compatible criteria is applied. After IBS diagnosis, step 1 therapy consisting of diet therapy, behavioral modification and gut-targeted pharmacotherapy is indicated for four weeks. Non-responders to step 1 therapy proceed to the second step that includes psychopharmacological agents and simple psychotherapy for four weeks. In the third step, for patients non-responsive to step 2 therapy, a combination of gut-targeted pharmacotherapy, psychopharmacological treatments and/or specific psychotherapy is/are indicated. Clinical guidelines and consensus for IBS treatment in Japan are well suited for Japanese IBS patients; as such, they may provide useful insight for IBS treatment in other countries around the world.

2 Guideline The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. 2014

Dumitrascu, Dan L / Chira, Alexandra / Bataga, Simona / Diculescu, Mircea / Drug, Vasile / Gheorghe, Cristian / Goldis, Adrian / Nedelcu, Laurentiu / Porr, Paul J / Sporea, Ioan / Anonymous290799. ·2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ddumitrascu@umfcluj.ro. · 2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · University of Medicine and Pharmacy, Tg-Mures, Romania. · Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. · Gr. T. Popa University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Iasi, Romania. · Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Timisoara, Romania. · Department of Internal Medicine, Transilvania University, Brasov, Romania. · Lucian Blaga University, Sibiu, Romania. · ·J Gastrointestin Liver Dis · Pubmed #25532003.

ABSTRACT: -- No abstract --

3 Guideline American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. 2014

Weinberg, David S / Smalley, Walter / Heidelbaugh, Joel J / Sultan, Shahnaz / Anonymous100911. ·Fox Chase Cancer Center, Philadelphia, Pennsylvania. · VA Tennessee Valley Healthcare System, Vanderbilt University, Nashville, Tennessee. · University of Michigan Ann Arbor, Michigan. · Department of Veterans Affairs Medical Center, Gastroenterology Section, North Florida/South Georgia Veterans Health System, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida; Minneapolis Veterans Affairs Health System, University of Minnesota, Minneapolis, Minnesota. · ·Gastroenterology · Pubmed #25224526.

ABSTRACT: -- No abstract --

4 Guideline [Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)]. 2013

Andresen, V / Layer, P / Anonymous1830764 / Anonymous1840764 / Anonymous1850764. · ·Z Gastroenterol · Pubmed #24266047.

ABSTRACT: -- No abstract --

5 Guideline Intestinal microbiota in functional bowel disorders: a Rome foundation report. 2013

Simrén, Magnus / Barbara, Giovanni / Flint, Harry J / Spiegel, Brennan M R / Spiller, Robin C / Vanner, Stephen / Verdu, Elena F / Whorwell, Peter J / Zoetendal, Erwin G / Anonymous880737. ·Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg S-41345, Sweden. magnus.simren@medicine.gu.se · ·Gut · Pubmed #22730468.

ABSTRACT: It is increasingly perceived that gut host-microbial interactions are important elements in the pathogenesis of functional gastrointestinal disorders (FGID). The most convincing evidence to date is the finding that functional dyspepsia and irritable bowel syndrome (IBS) may develop in predisposed individuals following a bout of infectious gastroenteritis. There has been a great deal of interest in the potential clinical and therapeutic implications of small intestinal bacterial overgrowth in IBS. However, this theory has generated much debate because the evidence is largely based on breath tests which have not been validated. The introduction of culture-independent molecular techniques provides a major advancement in our understanding of the microbial community in FGID. Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS. Investigators are also starting to measure host-microbial interactions in IBS. The current working hypothesis is that abnormal microbiota activate mucosal innate immune responses which increase epithelial permeability, activate nociceptive sensory pathways and dysregulate the enteric nervous system. While we await important insights in this field, the microbiota is already a therapeutic target. Existing controlled trials of dietary manipulation, prebiotics, probiotics, synbiotics and non-absorbable antibiotics are promising, although most are limited by suboptimal design and small sample size. In this article, the authors provide a critical review of current hypotheses regarding the pathogenetic involvement of microbiota in FGID and evaluate the results of microbiota-directed interventions. The authors also provide clinical guidance on modulation of gut microbiota in IBS.

6 Guideline British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. 2012

McKenzie, Y A / Alder, A / Anderson, W / Wills, A / Goddard, L / Gulia, P / Jankovich, E / Mutch, P / Reeves, L B / Singer, A / Lomer, M C E / Anonymous2900717. ·Nuffield Health The Manor Hospital, Oxford, UK Department of Nutrition and Dietetics, Royal Sussex County Hospital, Brighton, UK. · ·J Hum Nutr Diet · Pubmed #22489905.

ABSTRACT: BACKGROUND:  Irritable bowel syndrome (IBS) is a chronic debilitating functional gastrointestinal disorder. Diet and lifestyle changes are important management strategies. The aim of these guidelines is to systematically review key aspects of the dietary management of IBS, with the aim of providing evidence-based guidelines for use by registered dietitians. METHODS: Questions relating to diet and IBS symptom management were developed by a guideline development group. These included the role of milk and lactose, nonstarch polysaccharides (NSP), fermentable carbohydrates in abdominal bloating, probiotics and empirical or elimination diets. A comprehensive literature search was conducted and relevant studies from January 1985 to November 2009 were identified using the electronic database search engines: Cinahl, Cochrane Library, Embase, Medline, Scopus and Web of Science. Evidence statements, recommendations, good practice points and research recommendations were developed. RESULTS: Thirty studies were critically appraised. A dietetic care pathway was produced following a logical sequence of treatment and formed the basis of these guidelines. Three lines of dietary management were identified. first line: Clinical and dietary assessment, healthy eating and lifestyle management with some general advice on lactose and NSP. Second line: Advanced dietary interventions to improve symptoms based on NSP, fermentable carbohydrates and probiotics. Third line: Elimination and empirical diets. Research recommendations were also identified relating to the need for adequately powered and well designed randomised controlled trials. CONCLUSIONS: These guidelines provide evidence-based details of how to achieve the successful dietary management of IBS.

7 Guideline [IBD ahead 2010--Answering important questions in Crohn's disease treatment]. 2011

Schmidt, C / Dignass, A / Hartmann, F / Hüppe, D / Kruis, W / Layer, P / Lüers, A / Stallmach, A / Teich, N / Sturm, A / Anonymous1910696. ·Universitätklinikum Jena, Klinik für Innere Medizin II, Abteilung für Gastroenterologie, Hepatologie und Infektiologie. · ·Z Gastroenterol · Pubmed #21866492.

ABSTRACT: The treatment of patients with inflammatory bowel disease has become more complex in recent years through the introduction of various immunosuppressive agents as well as the approval of monoclonal antibodies against TNF-α and patients receiving such treatment must be carefully monitored. National and international guidelines define a diagnostic and therapeutic context for the practitioner, but can only partially respond to specific questions on the procedure for individual patients. Within the framework of a project initiated by Abbott entitled "IBD ahead" 38 German IBD experts have elaborated concrete proposals for dealing with corticosteroids, immunosuppressants and TNF-α antibodies on the basis of the published literature and their own personal experience in order to close the gap between these guidelines and daily clinical practice. Statements were developed on the choice of correct timing of initiation, dose and duration of the individual substances and on how to proceed with patients exhibiting treatment failure. Moreover, recommendations are also made on drug combination strategies, safety monitoring and the risks regarding the development of infectious complications and malignancies. These recommendations are illustrated by case studies from everyday practice in participating centres.

8 Guideline [Guidelines for the treatment of irritable bowel syndrome]. 2011

Kwon, Joong Goo / Park, Kyung Sik / Park, Jung Ho / Park, Jae Myung / Park, Cheol Hee / Lee, Kwang Jae / Park, Hyo Jin / Rhee, Jong Chul / Anonymous1970682. ·Department of Internal Medicine, Catholic University of Daegu School of Medicine, Korea. · ·Korean J Gastroenterol · Pubmed #21350320.

ABSTRACT: Traditional symptom-based therapies of irritable bowel syndrome (IBS) are directed at the relief of individual IBS symptoms, but they are often of limited efficacy in addressing the entire symptom complex. Combinations of drugs to target bothersome symptoms are suggested as the first-line pharmacologic treatment. Increasing knowledge of the pathophysiology and molecular mechanisms of IBS has resulted in the development of several new therapeutic approaches. Thirteen consensus statements for the treatment of IBS were developed using the modified Delphi approach. Exclusion diets have modest efficacy in improving symptoms in some IBS patients. Symptom-based therapies with dietary fiber, bulking agents, laxatives, antispasmodics and laxatives are effective in the improvement of some individual symptoms, e.g. dietary fiber and bulking agents for constipation, laxatives for constipation, antispasmodics for abdominal pain and discomfort, antidiarrheals for diarrhea. 5HT3 receptor antagonists and 5HT((4)) receptor agonists are effective in the relief of global IBS symptoms and individual symptoms such as abdominal pain and abnormal bowel habits. A short term course of nonabsorbable antibiotics may improve global IBS symptoms, particularly in patients with diarrhea- predominant IBS. Some probiotics appear to have the potential benefit in improving global IBS symptoms. Selective C-2 chloride channel activator is more effective than placebo at relieving global IBS symptoms in patients with constipation-predominant IBS. Both tricyclic antidepressants and selective serotonin reuptake inhibitors are equally effective in relieving global IBS symptoms, and have some benefits in treating abdominal pain. Certain types of psychologic therapy may be effective in improving global symptoms in some IBS patients. Further studies are strongly needed to develop better treatment strategies for Korean patients with IBS.

9 Guideline [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. 2011

Layer, P / Andresen, V / Pehl, C / Allescher, H / Bischoff, S C / Classen, M / Enck, P / Frieling, T / Haag, S / Holtmann, G / Karaus, M / Kathemann, S / Keller, J / Kuhlbusch-Zicklam, R / Kruis, W / Langhorst, J / Matthes, H / Mönnikes, H / Müller-Lissner, S / Musial, F / Otto, B / Rosenberger, C / Schemann, M / van der Voort, I / Dathe, K / Preiss, J C / Anonymous760681 / Anonymous770681. ·Für die Konsensusgruppe Reizdarmsyndrom; Konsensuskonferenz 18./ 19.9.2009. layer@ik-h.de · ·Z Gastroenterol · Pubmed #21287438.

ABSTRACT: -- No abstract --

10 Guideline Asian consensus on irritable bowel syndrome. 2010

Gwee, Kok-Ann / Bak, Young-Tae / Ghoshal, Uday Chand / Gonlachanvit, Sutep / Lee, Oh Young / Fock, Kwong Ming / Chua, Andrew Seng Boon / Lu, Ching-Liang / Goh, Khean-Lee / Kositchaiwat, Chomsri / Makharia, Govind / Park, Hyo-Jin / Chang, Full-Young / Fukudo, Shin / Choi, Myung-Gyu / Bhatia, Shobna / Ke, Meiyun / Hou, Xiaohua / Hongo, Michio / Anonymous4800663. ·Stomach Liver and Bowel Clinic, Gleneagles Hospital, Singapore. slbclinic@gmail.com · ·J Gastroenterol Hepatol · Pubmed #20594245.

ABSTRACT: BACKGROUND AND AIMS: Many of the ideas on irritable bowel syndrome (IBS) are derived from studies conducted in Western societies. Their relevance to Asian societies has not been critically examined. Our objectives were to bring to attention important data from Asian studies, articulate the experience and views of our Asian experts, and provide a relevant guide on this poorly understood condition for doctors and scientists working in Asia. METHODS: A multinational group of physicians from Asia with special interest in IBS raised statements on IBS pertaining to symptoms, diagnosis, epidemiology, infection, pathophysiology, motility, management, and diet. A modified Delphi approach was employed to present and grade the quality of evidence, and determine the level of agreement. RESULTS: We observed that bloating and symptoms associated with meals were prominent complaints among our IBS patients. In the majority of our countries, we did not observe a female predominance. In some Asian populations, the intestinal transit times in healthy and IBS patients appear to be faster than those reported in the West. High consultation rates were observed, particularly in the more affluent countries. There was only weak evidence to support the perception that psychological distress determines health-care seeking. Dietary factors, in particular, chili consumption and the high prevalence of lactose malabsorption, were perceived to be aggravating factors, but the evidence was weak. CONCLUSIONS: This detailed compilation of studies from different parts of Asia, draws attention to Asian patients' experiences of IBS.

11 Guideline Guidelines on the irritable bowel syndrome: mechanisms and practical management. 2007

Spiller, R / Aziz, Q / Creed, F / Emmanuel, A / Houghton, L / Hungin, P / Jones, R / Kumar, D / Rubin, G / Trudgill, N / Whorwell, P / Anonymous2230596. ·Wolfson Digestive Diseases Centre, University of Nottingham, Nottingham, UK. robin.spiller@nottingham.ac.uk · ·Gut · Pubmed #17488783.

ABSTRACT: BACKGROUND: IBS affects 5-11% of the population of most countries. Prevalence peaks in the third and fourth decades, with a female predominance. AIM: To provide a guide for the assessment and management of adult patients with irritable bowel syndrome. METHODS: Members of the Clinical Services Committee of The British Society of Gastroenterology were allocated particular areas to produce review documents. Literature searching included systematic searches using electronic databases such as Pubmed, EMBASE, MEDLINE, Web of Science, and Cochrane databases and extensive personal reference databases. RESULTS: Patients can usefully be classified by predominant bowel habit. Few investigations are needed except when diarrhoea is a prominent feature. Alarm features may warrant further investigation. Adverse psychological features and somatisation are often present. Ascertaining the patients' concerns and explaining symptoms in simple terms improves outcome. IBS is a heterogeneous condition with a range of treatments, each of which benefits a small proportion of patients. Treatment of associated anxiety and depression often improves bowel and other symptoms. Randomised placebo controlled trials show benefit as follows: cognitive behavioural therapy and psychodynamic interpersonal therapy improve coping; hypnotherapy benefits global symptoms in otherwise refractory patients; antispasmodics and tricyclic antidepressants improve pain; ispaghula improves pain and bowel habit; 5-HT(3) antagonists improve global symptoms, diarrhoea, and pain but may rarely cause unexplained colitis; 5-HT(4) agonists improve global symptoms, constipation, and bloating; selective serotonin reuptake inhibitors improve global symptoms. CONCLUSIONS: Better ways of identifying which patients will respond to specific treatments are urgently needed.

12 Guideline Clinical efficacy of probiotics: review of the evidence with focus on children. 2006

Anonymous7320570 / Michail, Sonia / Sylvester, Francisco / Fuchs, George / Issenman, Robert. · ·J Pediatr Gastroenterol Nutr · Pubmed #17033538.

ABSTRACT: Probiotics are marketed in several countries and widely used by pediatric health care providers. Although probiotics can be helpful for specific disorders, they have been broadly prescribed for disorders without clear evidence to support their use. Furthermore, in certain specific conditions, probiotics cause clinical deterioration. This report is a review and evaluation of the evidence or lack thereof to support a beneficial effect of probiotic agents in a variety of pediatric conditions and to review the safety and potential adverse events that may be encountered when using probiotics. It is also important to emphasize that probiotics are highly heterogeneous with differences in composition, biological activity, and dose among the different probiotic preparations.

13 Guideline [Clinical practice guideline for irritable bowel syndrome]. 2006

Tort, Sera / Balboa, Agustín / Marzo, Mercè / Carrillo, Ricard / Mínguez, Miguel / Valdepérez, Javier / Alonso-Coello, Pablo / Mascort, Juan José / Ferrándiz, Juan / Bonfill, Xavier / Piqué, Josep M / Mearin, Fermín / Anonymous5490570 / Anonymous5500570 / Anonymous5510570. ·Centro Cochrame Iberoamericano, Asociación Española de Gastroentología (AEG), Sociedad Española de Medicina de Familia y Comunitaria (SEMFYC). · ·Gastroenterol Hepatol · Pubmed #17020681.

ABSTRACT: -- No abstract --

14 Editorial [Fecal transplantation the future therapy?]. 2015

Rebizak, Ewelina / Sierant, Katarzyna / Łabuzek, Krzysztof / Okopień, Bogusław. ·Department of Internal Diseases and Clinical Pharmacology, Silesian. ·Pol Merkur Lekarski · Pubmed #26319378.

ABSTRACT: Intestinal bacteria play an important role in human physiology, taking part in the metabolism, absorption of nutrients and regulation of the immune system. In many illnesses the bacterial imbalance in the digestive tract occurs, and fecal transplantation is one method that allows you to restore the balance. The essence of the described method is to replace the pathogenesis, abnormal bacterial flora with the flora occurring in normal healthy individuals. So far, the main use of the method described in the article is resistant to antibiotics Clostridium difficile infection, which gives you a chance to avoid total colectomy. The article presents an accurate description of the same procedure to prepare the material, the selection of donor, recipient preparation and diseases, such as inflammatory bowel diseases, irritable bowel syndrome, diabetes and obesity, in which this method of treatment is currently practised.

15 Editorial A Moral Distress: Chewing Gum (Harmful or Helpful?). 2015

Brown, Geraldine. · ·ABNF J · Pubmed #26197629.

ABSTRACT: -- No abstract --

16 Editorial Editorial: fibre and FODMAPs in constipation and irritable bowel syndrome. 2015

Whelan, K. ·King's College London, Faculty of Life Sciences and Medicine, London, UK. kevin.whelan@kcl.ac.uk. ·Aliment Pharmacol Ther · Pubmed #26147109.

ABSTRACT: -- No abstract --

17 Editorial Immunomodulation of enteric neural function in irritable bowel syndrome. 2015

O'Malley, Dervla. ·Dervla O'Malley, Department of Physiology and Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland. ·World J Gastroenterol · Pubmed #26139983.

ABSTRACT: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which is characterised by symptoms such as bloating, altered bowel habit and visceral pain. It's generally accepted that miscommunication between the brain and gut underlies the changes in motility, absorpto-secretory function and pain sensitivity associated with IBS. However, partly due to the lack of disease-defining biomarkers, understanding the aetiology of this complex and multifactorial disease remains elusive. Anecdotally, IBS patients have noted that periods of stress can result in symptom flares and many patients exhibit co-morbid stress-related mood disorders such as anxiety and depression. However, in addition to psychosocial stressors, infection-related stress has also been linked with the initiation, persistence and severity of symptom flares. Indeed, prior gastrointestinal infection is one of the strongest predictors of developing IBS. Despite a lack of overt morphological inflammation, the importance of immune factors in the pathophysiology of IBS is gaining acceptance. Subtle changes in the numbers of mucosal immune cell infiltrates and elevated levels of circulating pro-inflammatory cytokines have been reproducibly demonstrated in IBS populations. Moreover, these immune mediators directly affect neural signalling. An exciting new area of research is the role of luminal microbiota in the modulation of neuro-immune signalling, resulting in local changes in gastrointestinal function and alterations in central neural functioning. Progress in this area has begun to unravel some of the complexities of neuroimmune and neuroendocrine interactions and how these molecular exchanges contribute to GI dysfunction.

18 Editorial Symptom Generation by Mucosal Inflammation in Irritable Bowel Syndrome. 2015

Sarna, Sushil K / Winston, John H. ·Department of Internal Medicine and Department of Neuroscience and Cell Biology, Enteric Neuromuscular Disorders and Visceral Pain Center, Division of Gastroenterology, The University of Texas Medical Branch at Galveston, Galveston, Texas. Electronic address: sksarna@utmb.edu. · Department of Internal Medicine, Enteric Neuromuscular Disorders and Visceral Pain Center, Division of Gastroenterology, The University of Texas Medical Branch at Galveston, Galveston, Texas. ·Gastroenterology · Pubmed #26116796.

ABSTRACT: -- No abstract --

19 Editorial Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome--possible and important?--Authors' reply. 2015

Talley, N J / Koloski, N A / Jones, M P. ·Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia. nicholas.talley@newcastle.edu.au. · Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia. · Department of Psychology, Macquarie University, North Ryde, NSW, Australia. ·Aliment Pharmacol Ther · Pubmed #25968151.

ABSTRACT: -- No abstract --

20 Editorial Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome--possible and important? 2015

Quigley, Eamonn M M. ·Gastroenterology and Hepatology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX, USA. equigley@tmhs.org. ·Aliment Pharmacol Ther · Pubmed #25968150.

ABSTRACT: -- No abstract --

21 Editorial Editorial: a new shift in the paradigm of treatment for the irritable bowel syndrome? 2015

Peters, S L / Gibson, P R. ·Department of Gastroenterology, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Vic., Australia. · Department of Gastroenterology, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Vic., Australia. peter.gibson@monash.edu. ·Aliment Pharmacol Ther · Pubmed #25968147.

ABSTRACT: -- No abstract --

22 Editorial [Complementary therapies in the guidelines for the treatment of irritable bowel syndrome]. 2015

Lauche, Romy / Cramer, Holger / Klose, Petra / Dobos, Gustav / Langhorst, Jost. ·Klinik für Naturheilkunde und Integrative Medizin, Kliniken Essen-Mitte, Medizinische Fakultät, Universität Duisburg-Essen, Essen, Deutschland. · ·Forsch Komplementmed · Pubmed #25824397.

ABSTRACT: -- No abstract --

23 Editorial Editorial: colesevelam effects on faecal bile acids in IBS with diarrhoea - author's reply. 2015

Camilleri, M. ·Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, USA. camilleri.michael@mayo.edu. ·Aliment Pharmacol Ther · Pubmed #25736145.

ABSTRACT: -- No abstract --

24 Editorial Editorial: colesevelam effects on faecal bile acids in IBS with diarrhoea. 2015

Walters, J R F / Appleby, R N. ·Imperial College London & Imperial College Healthcare NHS Trust, London, UK. julian.walters@imperial.ac.uk. · ·Aliment Pharmacol Ther · Pubmed #25736144.

ABSTRACT: -- No abstract --

25 Editorial American college of gastroenterology monograph on the management of irritable bowel syndrome. 2015

Camilleri, Michael. ·Mayo Clinic , Charlton 8-110, 200 First St. S.W. Rochester, MN 55905 , USA +1 507 266 2305 ; camilleri.michael@mayo.edu. ·Expert Opin Pharmacother · Pubmed #25582735.

ABSTRACT: This editorial reviews a recently published guideline on management of irritable bowel syndrome. The guideline illustrates problems arising from the quality of clinical trials used in systematic reviews and the potential impact of the inherent weaknesses of those trials on rating the strength of evidence and the resulting recommendations.

Next